Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Lilly | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Lilly

Revenue up 15% in the quarter due to key growth products Trulicity, Taltz, Verzenio, Emgality, Basaglar, Jardiance, and Baqsimi

By: Contract Pharma

Contract Pharma Staff

Lilly

1Q Revenues: $5.9 billion (+15%)

1Q Earnings: $1.5 billion (-66%)

Comments: Trulicity sales were up 40% to $1.2 billion driven by increased volume, partially offset by lower realized prices. Humalog sales were $695.8 million, down 5% driven primarily by lower realized prices due to changes in estimates for rebates and discounts and changes in segment mix, partially offset by increased volume. Alimta sales were $560.1million, up 12% primarily driven by increased volume. Talz sales were $443.5 million, up 76% driven by increased volume. Humulin sales were $315.7 million, up 6% driven by increased volume, partially offset by lower realized prices. Revenue in the U.S. increased 15%, to $3.3 billion. Key growth products, include Trulicity, Taltz, Verzenio, Emgality, Basaglar, Jardiance, and Baqsimi, as well as for Humalog, was partially offset by decreased volume for Cialis due to loss of patent exclusivity. The company estimates that U.S. volume growth in the first quarter was favorably impacted by increased customer buying patterns and patient prescription trends resulting from the COVID-19 pandemic that increased U.S. revenue by approximately $200 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters